Combination Topical Tranexamic Acid and Vitamin C for the Treatment of Refractory Melasma.
Melasma
Topical tranexamic acid
Vitamin C
Journal
The Journal of clinical and aesthetic dermatology
ISSN: 1941-2789
Titre abrégé: J Clin Aesthet Dermatol
Pays: United States
ID NLM: 101518173
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Melasma is a widespread condition that affects people of many ethnicities and is prevalent in the Middle East. To date, the therapeutic arsenal is still not effective, especially in countries with high ultraviolet light index. New treatment options are needed. The aim of this pilot study was to assess the efficacy of topical tranexamic acid (TA) 2% combined with vitamin C 2% in the treatment of resistant melasma in the Mediterranean region. This prospective interventional pilot study included 10 women, aged 18 to 55 years, with resistant melasma. Intervention consisted in application of a topical formulation containing 2% TA and 2% vitamin C, every night for eight weeks. The primary outcome was the Melasma Area and Severity Index (MASI) score measured at baseline and at Weeks 4 and 8. Melasma Quality of Life Scale (MelasQoL) and Physician Global Assessment (PGA) were used at baseline and at Weeks 4 and 8 of treatment, and they were set as the secondary outcomes. The mean MASI score varied from 12.76±3.91 at baseline to 7.00±4.85 at Week 4 ( Our pilot study demonstrated the possibility of a topical combination of TA 2% and vitamin C 2 %, which may be a useful therapeutic strategy in the treatment of resistant melasma in the Middle east, a region of the world with high UV index. This combination treatment is a safer alternative to dangerous bleaching treatments that are still being used.
Sections du résumé
Background
UNASSIGNED
Melasma is a widespread condition that affects people of many ethnicities and is prevalent in the Middle East. To date, the therapeutic arsenal is still not effective, especially in countries with high ultraviolet light index. New treatment options are needed.
Objective
UNASSIGNED
The aim of this pilot study was to assess the efficacy of topical tranexamic acid (TA) 2% combined with vitamin C 2% in the treatment of resistant melasma in the Mediterranean region.
Methods
UNASSIGNED
This prospective interventional pilot study included 10 women, aged 18 to 55 years, with resistant melasma. Intervention consisted in application of a topical formulation containing 2% TA and 2% vitamin C, every night for eight weeks. The primary outcome was the Melasma Area and Severity Index (MASI) score measured at baseline and at Weeks 4 and 8. Melasma Quality of Life Scale (MelasQoL) and Physician Global Assessment (PGA) were used at baseline and at Weeks 4 and 8 of treatment, and they were set as the secondary outcomes.
Results
UNASSIGNED
The mean MASI score varied from 12.76±3.91 at baseline to 7.00±4.85 at Week 4 (
Conclusion
UNASSIGNED
Our pilot study demonstrated the possibility of a topical combination of TA 2% and vitamin C 2 %, which may be a useful therapeutic strategy in the treatment of resistant melasma in the Middle east, a region of the world with high UV index. This combination treatment is a safer alternative to dangerous bleaching treatments that are still being used.
Types de publication
Journal Article
Langues
eng
Pagination
63-65Informations de copyright
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Déclaration de conflit d'intérêts
DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article.
Références
Acta Derm Venereol. 2010 May;90(3):331-2
pubmed: 20526570
J Am Acad Dermatol. 2007 Jun;56(6):933-8
pubmed: 17321004
Acta Derm Venereol. 2017 Jul 6;97(7):776-781
pubmed: 28374042
J Clin Aesthet Dermatol. 2022 May;15(5):19-28
pubmed: 35642229
Health Sci Rep. 2022 Mar 09;5(2):e537
pubmed: 35284654
J Res Med Sci. 2014 Aug;19(8):753-7
pubmed: 25422661
An Bras Dermatol. 2014 Sep-Oct;89(5):771-82
pubmed: 25184917
J Clin Aesthet Dermatol. 2016 Jan;9(1):21-4
pubmed: 26962388
J Cosmet Dermatol. 2020 Jan;19(1):147-153
pubmed: 31058398
PLoS One. 2022 Jan 27;17(1):e0262833
pubmed: 35085327
J Cosmet Dermatol. 2019 Oct;18(5):1342-1347
pubmed: 30770637
J Cosmet Sci. 2020 Sep/Oct;71(5):263-290
pubmed: 33022197